Celcuity Inc. (CELC)

Market Cap	4.72B
Revenue (ttm)	n/a
Net Income (ttm)	-162.72M
Shares Out	46.27M
EPS (ttm)	-3.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,793
Open	101.17
Previous Close	102.25
Day's Range	98.76 - 102.37
52-Week Range	7.58 - 112.64
Beta	0.22
Analysts	Strong Buy
Price Target	100.13 (-1.82%)
Earnings Date	Nov 12, 2025

About CELC

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 87
• Stock Exchange: NASDAQ
• Ticker Symbol: CELC
• Website: https://www.celcuity.com

Analyst Summary

According to 8 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $100.13, which is a decrease of -1.82% from the latest price.

Price Target

$100.13

(-1.82% downside)

Analyst Consensus: Strong Buy